Long-term outcomes of gastrografin in small bowel obstruction

Yaser M K Baghdadi, Asad J. Choudhry, Naeem Goussous, Mohammad A. Khasawneh, Stephanie F. Polites, Martin D. Zielinski

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background The gastrografin (GG) challenge is a diagnostic and therapeutic tool used to treat patients with small bowel obstruction (SBO); however, long-term data on SBO recurrence after the GG challenge remain limited. We hypothesized that patients treated with GG would have the same long-term recurrence as those treated before the implementation of the GG challenge protocol. Methods Patients ≥18 years who were treated for SBO between July 2009 and December 2012 were identified. We excluded patients with contraindications to the GG challenge (i.e., signs of strangulation), patients having SBO within 6-wk of previous abdominal or pelvic surgery and patients with malignant SBO. All patients had been followed a minimum of 1 y or until death. Kaplan-Meier method and Cox regression models were used to describe the time-dependent outcomes. Results A total of 202 patients were identified of whom 114 (56%) received the challenge. Mean patients age was 66 y (range, 19-99 y) with 110 being female (54%). A total of 184 patients (91%) were followed minimum of 1 year or death (18 patients lost to follow-up). Median follow-up of living patients was 3 y (range, 1-5 y). During follow-up, 50 patients (25%) experienced SBO recurrences, and 24 (12%) had exploration for SBO recurrence. The 3-year cumulative rate of SBO recurrence in patients who received the GG was 30% (95% confidence interval [CI], 21%-42%) compared to 27% (95% CI, 18%-38%) for those who did not (P = 0.4). The 3-year cumulative rate of exploration for SBO recurrence in patients who received the GG was 15% (95% CI, 8%-26%) compared to 12 % (95% CI, 6%-22%) for those who did not (P = 0.6). Conclusions The GG challenge is a clinically useful tool in treating SBO patients with comparable long-term recurrence rates compared to traditional management of SBO.

Original languageEnglish (US)
Pages (from-to)43-48
Number of pages6
JournalJournal of Surgical Research
Volume202
Issue number1
DOIs
StatePublished - May 1 2016

Fingerprint

Diatrizoate Meglumine
Recurrence
Confidence Intervals
Lost to Follow-Up

Keywords

  • Gastrografin
  • Outcomes
  • Recurrence
  • Small bowel obstruction

ASJC Scopus subject areas

  • Surgery

Cite this

Baghdadi, Y. M. K., Choudhry, A. J., Goussous, N., Khasawneh, M. A., Polites, S. F., & Zielinski, M. D. (2016). Long-term outcomes of gastrografin in small bowel obstruction. Journal of Surgical Research, 202(1), 43-48. https://doi.org/10.1016/j.jss.2015.11.017

Long-term outcomes of gastrografin in small bowel obstruction. / Baghdadi, Yaser M K; Choudhry, Asad J.; Goussous, Naeem; Khasawneh, Mohammad A.; Polites, Stephanie F.; Zielinski, Martin D.

In: Journal of Surgical Research, Vol. 202, No. 1, 01.05.2016, p. 43-48.

Research output: Contribution to journalArticle

Baghdadi, YMK, Choudhry, AJ, Goussous, N, Khasawneh, MA, Polites, SF & Zielinski, MD 2016, 'Long-term outcomes of gastrografin in small bowel obstruction', Journal of Surgical Research, vol. 202, no. 1, pp. 43-48. https://doi.org/10.1016/j.jss.2015.11.017
Baghdadi YMK, Choudhry AJ, Goussous N, Khasawneh MA, Polites SF, Zielinski MD. Long-term outcomes of gastrografin in small bowel obstruction. Journal of Surgical Research. 2016 May 1;202(1):43-48. https://doi.org/10.1016/j.jss.2015.11.017
Baghdadi, Yaser M K ; Choudhry, Asad J. ; Goussous, Naeem ; Khasawneh, Mohammad A. ; Polites, Stephanie F. ; Zielinski, Martin D. / Long-term outcomes of gastrografin in small bowel obstruction. In: Journal of Surgical Research. 2016 ; Vol. 202, No. 1. pp. 43-48.
@article{34012862ded546b390540b22d2ee8da4,
title = "Long-term outcomes of gastrografin in small bowel obstruction",
abstract = "Background The gastrografin (GG) challenge is a diagnostic and therapeutic tool used to treat patients with small bowel obstruction (SBO); however, long-term data on SBO recurrence after the GG challenge remain limited. We hypothesized that patients treated with GG would have the same long-term recurrence as those treated before the implementation of the GG challenge protocol. Methods Patients ≥18 years who were treated for SBO between July 2009 and December 2012 were identified. We excluded patients with contraindications to the GG challenge (i.e., signs of strangulation), patients having SBO within 6-wk of previous abdominal or pelvic surgery and patients with malignant SBO. All patients had been followed a minimum of 1 y or until death. Kaplan-Meier method and Cox regression models were used to describe the time-dependent outcomes. Results A total of 202 patients were identified of whom 114 (56{\%}) received the challenge. Mean patients age was 66 y (range, 19-99 y) with 110 being female (54{\%}). A total of 184 patients (91{\%}) were followed minimum of 1 year or death (18 patients lost to follow-up). Median follow-up of living patients was 3 y (range, 1-5 y). During follow-up, 50 patients (25{\%}) experienced SBO recurrences, and 24 (12{\%}) had exploration for SBO recurrence. The 3-year cumulative rate of SBO recurrence in patients who received the GG was 30{\%} (95{\%} confidence interval [CI], 21{\%}-42{\%}) compared to 27{\%} (95{\%} CI, 18{\%}-38{\%}) for those who did not (P = 0.4). The 3-year cumulative rate of exploration for SBO recurrence in patients who received the GG was 15{\%} (95{\%} CI, 8{\%}-26{\%}) compared to 12 {\%} (95{\%} CI, 6{\%}-22{\%}) for those who did not (P = 0.6). Conclusions The GG challenge is a clinically useful tool in treating SBO patients with comparable long-term recurrence rates compared to traditional management of SBO.",
keywords = "Gastrografin, Outcomes, Recurrence, Small bowel obstruction",
author = "Baghdadi, {Yaser M K} and Choudhry, {Asad J.} and Naeem Goussous and Khasawneh, {Mohammad A.} and Polites, {Stephanie F.} and Zielinski, {Martin D.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.jss.2015.11.017",
language = "English (US)",
volume = "202",
pages = "43--48",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Long-term outcomes of gastrografin in small bowel obstruction

AU - Baghdadi, Yaser M K

AU - Choudhry, Asad J.

AU - Goussous, Naeem

AU - Khasawneh, Mohammad A.

AU - Polites, Stephanie F.

AU - Zielinski, Martin D.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background The gastrografin (GG) challenge is a diagnostic and therapeutic tool used to treat patients with small bowel obstruction (SBO); however, long-term data on SBO recurrence after the GG challenge remain limited. We hypothesized that patients treated with GG would have the same long-term recurrence as those treated before the implementation of the GG challenge protocol. Methods Patients ≥18 years who were treated for SBO between July 2009 and December 2012 were identified. We excluded patients with contraindications to the GG challenge (i.e., signs of strangulation), patients having SBO within 6-wk of previous abdominal or pelvic surgery and patients with malignant SBO. All patients had been followed a minimum of 1 y or until death. Kaplan-Meier method and Cox regression models were used to describe the time-dependent outcomes. Results A total of 202 patients were identified of whom 114 (56%) received the challenge. Mean patients age was 66 y (range, 19-99 y) with 110 being female (54%). A total of 184 patients (91%) were followed minimum of 1 year or death (18 patients lost to follow-up). Median follow-up of living patients was 3 y (range, 1-5 y). During follow-up, 50 patients (25%) experienced SBO recurrences, and 24 (12%) had exploration for SBO recurrence. The 3-year cumulative rate of SBO recurrence in patients who received the GG was 30% (95% confidence interval [CI], 21%-42%) compared to 27% (95% CI, 18%-38%) for those who did not (P = 0.4). The 3-year cumulative rate of exploration for SBO recurrence in patients who received the GG was 15% (95% CI, 8%-26%) compared to 12 % (95% CI, 6%-22%) for those who did not (P = 0.6). Conclusions The GG challenge is a clinically useful tool in treating SBO patients with comparable long-term recurrence rates compared to traditional management of SBO.

AB - Background The gastrografin (GG) challenge is a diagnostic and therapeutic tool used to treat patients with small bowel obstruction (SBO); however, long-term data on SBO recurrence after the GG challenge remain limited. We hypothesized that patients treated with GG would have the same long-term recurrence as those treated before the implementation of the GG challenge protocol. Methods Patients ≥18 years who were treated for SBO between July 2009 and December 2012 were identified. We excluded patients with contraindications to the GG challenge (i.e., signs of strangulation), patients having SBO within 6-wk of previous abdominal or pelvic surgery and patients with malignant SBO. All patients had been followed a minimum of 1 y or until death. Kaplan-Meier method and Cox regression models were used to describe the time-dependent outcomes. Results A total of 202 patients were identified of whom 114 (56%) received the challenge. Mean patients age was 66 y (range, 19-99 y) with 110 being female (54%). A total of 184 patients (91%) were followed minimum of 1 year or death (18 patients lost to follow-up). Median follow-up of living patients was 3 y (range, 1-5 y). During follow-up, 50 patients (25%) experienced SBO recurrences, and 24 (12%) had exploration for SBO recurrence. The 3-year cumulative rate of SBO recurrence in patients who received the GG was 30% (95% confidence interval [CI], 21%-42%) compared to 27% (95% CI, 18%-38%) for those who did not (P = 0.4). The 3-year cumulative rate of exploration for SBO recurrence in patients who received the GG was 15% (95% CI, 8%-26%) compared to 12 % (95% CI, 6%-22%) for those who did not (P = 0.6). Conclusions The GG challenge is a clinically useful tool in treating SBO patients with comparable long-term recurrence rates compared to traditional management of SBO.

KW - Gastrografin

KW - Outcomes

KW - Recurrence

KW - Small bowel obstruction

UR - http://www.scopus.com/inward/record.url?scp=84960863838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960863838&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2015.11.017

DO - 10.1016/j.jss.2015.11.017

M3 - Article

VL - 202

SP - 43

EP - 48

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -